Moffitt Cancer Center is a proud supporter and corporate partner of C3 For Change. The center’s health informatics subsidiary, M2Gen, recently received an equity investment by Hearst, a leader in healthcare technology. Check out a portion of the press release, below.
NEW YORK and TAMPA, FLA. — Hearst, a market leader in healthcare technology, announced an equity investment in M2Gen, a health informatics subsidiary of Moffitt Cancer Center, one of the top comprehensive cancer centers in the United States. This partnership will help accelerate the discovery of innovative cancer therapies and improve care for patients nationwide. The collaboration will provide funding to expand the efforts of the nation’s first major data sharing network among leading cancer institutions.
“Hearst is committed to investing in companies and solutions whose information and analytics can improve and advance healthcare,” said Hearst President and CEO Steven R. Swartz. “M2Gen is making enormous strides in advancing cancer research through its pioneering work, and we are proud to join this mission.”
As one of the top-ranked cancer centers in the nation, Moffitt is world-renowned for its ability to take groundbreaking research and translate it to treatments at the patient’s bedside. A pioneer in big data for healthcare, M2Gen’s innovative Total Cancer Care (TCC) protocol was developed to enable better research of cancer and patients, tracking each patient throughout his or her lifetime, and using this information to drive novel therapies and advancements in care. Cancer therapy researchers gain access to this clinical and genetic information to help accelerate new drug discovery and match cancer patients to clinical trials.
This article originally posted on Moffitt.org.
